SKSuvarna Ganesh Kini

Suvarna Ganesh Kini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Suvarna Ganesh Kini has a total of 141 co-authors. Here are the top co-authors by number of shared publications:

  • Ekta Rathi

    Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education (MAHE), Manipal, Karnataka 576104, India

    15 shared publications
  • Avinash Kumar

    Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India

    14 shared publications
  • Avinash Kumar

    Department of Medical Affairs, Curie Sciences Private Limited, Samastipur, India

    7 shared publications
  • Ekta Rathi

    Department of Pharmaceutical Chemistry Manipal Karnataka 576104 Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education

    7 shared publications
  • Karkala Sreedhara Ranganath Pai

    Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India

    4 shared publications
  • Mangala Shenoy K.

    Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India

    4 shared publications

Latest Publications

  • Integrated in silico and population modelling of DF250513, a standardized polyherbal ayurvedic formulation for type 2 diabetes

    by Payel Mal, Tulsi Chandak, Deeksha Bhat, Saikumar Jurra, Hari Venkatesh, Sasibhushan Vedula, Suprabha Hegde, Venkatesh Kareenhalli, Karan Bhagchand, Sanjaay Balakrishnan, et al.

  • Mechanistic Evaluation of Abutilon indicum Extract and Syringaldehyde in Ovalbumin-Induced Airway Inflammation Using Computational and Experimental Approaches

    by B. C. Mamatha, S. Vijaya Kumar, Pavithra Pradeep Prabhu, Akhil Nair, K. Mangala Shenoy, Suvarna Kini, Wilona Loren Lobo, Nitha Naveen Dsouza, Srikanth Jupudi, Ashwini Prabhu, et al.

    Abutilon indicum Linn. is a traditionally used medicinal herb in the treatment of inflammatory diseases. Syringaldehyde (SYD) is a major phytoconstituent of A. indicum. To compare the mast cell stabilizing and anti-asthmatic effects of hydroalcoholic extract of A. indicum (HAEAI) and SYD, and to explore the possible molecular mechanisms. Compound 48/80 (C48/80) induced mesenteric mast cell degranulation in rats was evaluated after 7 days of SYD (25 mg/kg and 50 mg/kg) and HAEAI (200 mg/kg and 400 mg/kg). Anti-asthmatic activity was assessed in ovalbumin (OVA)-induced allergic asthma in mice, with SYD and HAEAI administered during the challenge phase. Inflammatory cell counts in blood and bronchoalveolar lavage fluid (BALF) were quantified. BALF Th2 cytokines (IL-4 and IL-13) and serum OVA-specific IgE were measured by ELISA, and lung histopathology was performed. Network pharmacology, molecular docking, and molecular dynamics simulation were used for mechanistic evaluation. SYD and HAEAI showed a substantial effect by inhibiting C48/80-induced degranulation of mast cells ([Formula: see text] < 0.0001). In OVA-challenged mice, both treatments decreased inflammatory cell infiltration in BALF and blood, compared with the inducer control group, which showed elevated BALF cytokine levels of IL-4 (98.50 ± 6.56 pg/mL) and IL-13 (159.91 ± 9.56 pg/mL); treatment with HAEAI and SYD significantly reduced these inflammatory markers. HAEAI decreased IL-4 levels to 84.95 ± 3.73 pg/mL at the low dose and 67.20 ± 3.02 pg/mL at the high dose, while SYD reduced IL-4 levels to 66.91 ± 3.88 pg/mL and 55.90 ± 3.32 pg/mL at the low and high doses, respectively. Similarly, HAEAI reduced IL-13 levels to 143.50 ± 6.96 pg/mL at the low dose and 91.83 ± 9.06 pg/mL at the high dose, whereas SYD lowered IL-13 levels to 118.42 ± 4.86 pg/mL and 55.69 ± 3.74 pg/mL at the low and high doses, respectively. In addition, serum OVA-specific IgE levels were markedly reduced in the treatment groups compared with the inducer control group (557.84 ± 3.39 ng/mL). HAEAI reduced IgE levels to 378.44 ± 1.94 ng/mL at the low dose and 180.90 ± 1.30 ng/mL at the high dose. SYD also lowered serum OVA-specific IgE levels to 323.56 ± 1.93 ng/mL and 222.15 ± 1.55 ng/mL at the low and high doses, respectively. These findings indicate that both HAEAI and SYD exert significant anti-allergic effects by suppressing Th2 cytokines and reducing OVA-specific IgE production. and improved lung histopathology. In silico analysis showed a multi-target effect on allergic and inflammatory signaling. Following docking, a favorable ligand–protein interaction was observed during simulation. SYD and HAEAI have good mast cell stabilizing and anti-asthmatic effects, likely mediated through suppression of Th2-induced inflammation and multi-targeting allergic signaling pathways.

  • Open Access

    Flavonoids from Clitoria ternatea as Promising Therapeutic Agents against Ovarian Cancer

    by Mangala Shenoy K, Ekta Rathi, Pooja Mallya, Vinay C Sangamesh, Pavithra Pradeep Prabhu, Shaila A Lewis, Govindarajan R, Suvarna G Kini

    Background Flavonoid-based natural products have shown promising anti-cancer potential through dual-pathway inhibition. The PI3K/AKT/mTOR signaling pathway is the most frequently altered pathway in ovarian cancer, making it a critical therapeutic target. Methods Extensive computational studies including molecular docking and 200 nanosecond molecular dynamics simulations were conducted to evaluate the binding affinity, interaction stability, and conformational dynamics of the PI3K (5DXT) and mTOR (5GPG) proteins. Following in-silico validation, naringin-coated zinc oxide nanoparticles incorporating Clitoria ternatea flower extract were formulated to enhance bioavailability and therapeutic efficacy. Additionally, cytotoxic evaluation against SKOV3 ovarian cancer cell lines using MTT assay was performed. Results This study investigated the efficacy of major flavonoid components from Clitoria ternatea flowers, specifically quercetin-3-rutinoside and quercetin-3,7-glucoside, as dual PI3K/mTOR inhibitors. Molecular dynamics analysis revealed that quercetin-3-rutinoside and quercetin-3,7-glucoside exhibited stable interactions with critical amino acid residues throughout the simulation period, promising enhanced stability compared with the standard dual inhibitor gedatolisib. Absorption, Distribution, Metabolism, and Excretion (ADME) profiling identified quercetin derivatives as promising lead hits, despite minor violations of Lipinski’s Rule of Five. Cytotoxic evaluation against SKOV3 ovarian cancer cell lines using MTT assay demonstrated the superior performance of naringin-coated nanoparticles (NC1) with an IC₅₀ value of 144 ± 2.43 μg/mL. Conclusion This synergistic approach, combining natural flavonoids with nanotechnology, provides a novel therapeutic strategy for targeting the dysregulated PI3K/mTOR pathway in ovarian cancer. These findings establish Clitoria ternatea flavonoids are superior candidates for the development of enhanced nanoformulations for anti-cancer therapeutics against ovarian cancer.

  • Multi-Level Computational Screening of Citrus Flavonoids as Promising Inhibitors Against Ovarian Cancer

    by Mangala Shenoy K, Pavithra Pradeep Prabhu, Ekta Rathi, Prarambh S. R. Dwivedi, Akhil Nair, Suvarna G. Kini

    Citrus fruits and their bioactive components have demonstrated significant therapeutic potential in the management of various diseases. The present study aims to identify potent citrus flavonoids that could act as dual PI3K/mTOR inhibitors against ovarian cancer. Using a network pharmacology framework, the potential targets of citrus flavonoids were mapped against genes associated with ovarian cancer, revealing key pathway enrichment within the PI3K/mTOR signaling cascade. A natural compound library derived from the Eximed database was employed for the study, and High-Throughput Virtual Screening (HTVS) was performed to identify compounds showing favorable interactions with PI3K (PDB ID: 5DXT) and mTOR (PDB ID: 5GPB). Based on Standard Precision (SP) and extra precision (XP) docking results, hesperidin was identified as a promising candidate for further investigation. Additionally, two other flavonoids, hesperetin and naringin, were selected based on literature evidence. Further computational analyses, including MM-GBSA binding free energy calculations, ADME prediction, molecular dynamics simulations and water map analysis, indicated that hesperidin exhibits strong binding stability and favorable interaction profiles. These findings suggest that hesperidin may serve as a promising lead compound for further in-vitro and in-vivo studies aimed at developing effective dual PI3K/mTOR inhibitors against ovarian cancer therapy.

  • Bisquinoline as a promising scaffold in anti-infective drug discovery: the current state of the art and future prospects

    by Swagatika Dash, Suvarna G Kini, Amit Sharma

    Bisquinoline is a privileged pharmacophore in medicinal chemistry due to its diverse biological activities, particularly against infectious diseases such as malaria, tuberculosis, leishmania, fungi, bacteria, protozoa, schistosomiasis, and HIV. The success of piperaquine, a bisquinoline-derived antimalarial, has underscored its therapeutic potential, driving interest in its role as a small-molecule probe for targeting critical disease pathways. As drug resistance increases and the need for effective treatments rises, bisquinoline's broad pharmacological profile presents promising drug discovery opportunities. This review explores research on bisquinoline derivatives as anti-infective agents, focusing on synthetic approaches, detailed structure-activity relationships, and therapeutic applications. It includes detailed insights into piperaquine, the only approved bisquinoline drug, based on literature from 2000 to 2025 sourced from PubMed, Scopus, and Web of Science concerning 'bisquinoline scaffold' keywords. In the last two decades, significant progress has been made in developing bisquinoline derivatives with various pharmacological effects. These advancements have expanded our understanding of the scaffold's pharmacological diversity and its potential for creating more effective drugs with fewer side effects. This continued progression will aid the development of the next-generation of bisquinoline-based therapeutics.

  • Open Access

    Structure–activity relationships of KRAS-G12D inhibitors for pancreatic cancer

    by Chetna Suyal, K. Mangala Shenoy, Anoop Kishore, Suvarna G. Kini


  • Open Access

    Design of PI3K-mTOR Dual Inhibitors for Ovarian Cancer: Are we on the Right Track?

    by Mangala Shenoy K., Ekta Rathi, Karthik S. Udupa, Shama Prasada K., K. Sreedhara Ranganath Pai, Suvarna Ganesh Kini

    Ovarian cancer is one of the most familiar kinds of gynecological cancer seen in women. Though it is not as familiar as breast cancer, the survival rate for ovarian cancer is very low when compared with breast cancer. Even after being one among the familiar types, to date, there are no proper treatments available for ovarian cancer. All the treatments that are present currently show a high rate of recurrence after the treatment. Therefore, treating this silent killer from the roots is the need of the hour. PI3K/AKT/m-TOR pathway is one of the pathways that get altered during ovarian cancer. Studies are already going on for the inhibition of PI3K and mTOR separately. Efforts have been made to inhibit either PI3K or mTOR separately earlier. However, due to its side effects and resistance to the treatments available, current studies are based on the inhibition of PI3K and mTOR together. Inhibition of PI3K and mTOR simultaneously reduces the chances of negative feedback, thus decreasing the toxicity. This review contains the evolution of PI3K and mTOR drugs that are approved by the FDA and are in the trials for different cancer types, including ovarian cancer. In this article, how a molecular targeted therapy can be made successful and free from toxicity for treating ovarian cancer is discussed. Therefore, this review paves the way for finding an effective scaffold rather than the clinical part. The scaffold thus selected can be further modified and synthesized in the future as dual PI3K/mTOR inhibitors specifically for OC.


  • Open Access

    Immunoinformatics design of a multi-epitope vaccine for Chlamydia trachomatis major outer membrane proteins

    by Seema Shetty, Swagatika Dash, Avinash Kumar, Shashidhar Vishwanath, Suvarna G. Kini, Angela Brand

    Chlamydia trachomatis (CT) remains a significant infectious cause of blindness and sexually transmitted infections worldwide. The objective and novelty of this study lie in using different serovars of CT to design a broad-spectrum multi-epitope vaccine that might confer immunity against different CT infections. As the major outer membrane protein in CT has good immunodominance properties and high conservation and also determines the several serotypes of CT, it is selected as an antibody target in this study. T-cell and B-cell epitopes from serovars A, B, D, E, L1, and L2 were predicted and combined into a single construct by incorporating adjuvants and linkers to enhance immunogenicity and stability. Physicochemical characterization confirmed the constructed vaccine’s anti-allergic, immunogenicity, and thermostable characteristics, followed by structural modeling to refine its 3D configuration. The 3D model structure of the vaccine was validated through the Ramachandran plot and ProSA z-score. Molecular docking studies of the vaccine demonstrated stable binding with toll-like receptor 3, along with molecular dynamics simulations and binding free energy calculations supporting the complex’s stability. In silico cloning has indicated a high potential for expression in Escherichia coli. Lastly, immune simulations revealed robust activation of B cells, cytotoxic T cells, and antigen-presenting cells, alongside significant production of IgM, IgG antibodies, and balanced Th1/Th2 cytokine response, which is crucial for effective immunity. These results suggest the multi-epitope vaccine could effectively induce comprehensive immune responses against CT, highlighting the need for further in vivo validation to advance this promising candidate toward clinical use.